Sandu Pharmaceuticals Ltd (SANDUPHQ) — shareholding pattern, promoter holding, financials and share price
About Sandu Pharmaceuticals Ltd (SANDUPHQ)
Sandu Pharmaceuticals Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as SANDUPHQ and on the BSE under scrip code 524703. Its ISIN is INE751D01014.
Incorporated in 1985, Sandu Pharmaceuticals Ltd is a manufacturer of Ayurvedic Medicines. [1]
Sandu Pharmaceuticals Ltd (SPL) is primarily engaged in the manufacturing and trading of Ayurvedic medicines, operating under its brand name SANDU.
Established in 1985, SPL expanded its capabilities with a major project in Goa, initiated in 1994 and commenced production in 1996-97, marking a significant milestone in the company's growth journey.
Listed peers in Pharmaceuticals: ANG Lifesciences India Ltd, Rajnish Wellness Ltd, Lasa Supergenerics Ltd, Roopa Industries Ltd, JFL Life Sciences Ltd.
Valuation & Returns
10 Jul 2026At ₹41 a share on 10 Jul 2026, Sandu Pharmaceuticals Ltd (SANDUPHQ) was valued at a price-to-earnings ratio of 25.39x against an industry P/E of 36.41x and a price-to-book of 0.94x on a book value of ₹43.49 per share as of Mar 2025. Solomo computes return on equity of 3.71% and return on capital employed of 5.38% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2024 to Mar 2025.
- P/E
- 25.39x
- Industry P/E
- 36.41x
- P/B
- 0.94x
- EPS (TTM)
- ₹1.61
- Book value / share
- ₹43.49
- ROE
- 3.71%
- ROCE
- 5.38%
- ROA
- 2.8%
- Debt / equity
- 0x
- Dividend yield
- 1.95%
- EBITDA margin
- 4.36%
- 52-week range
- ₹40.67 – ₹41.47
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2025In the year ended Mar 2025, Sandu Pharmaceuticals Ltd (SANDUPHQ) reported revenue of ₹67.19 crore, net profit of ₹1.55 crore and earnings per share of ₹1.6. That compares with revenue of ₹67.28 crore and net profit of ₹1.46 crore in Mar 2024. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2025, revenue was ₹14.07 crore and net profit ₹0.33 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Revenue (₹ cr) | 65.5 | 65.35 | 67.28 | 67.19 |
| Net profit (₹ cr) | 1.59 | 1.52 | 1.46 | 1.55 |
| EPS (₹) | 1.8 | 1.57 | 1.51 | 1.6 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 5.41% | 6.80% | 0.85% | -0.13% |
| Profit growth | 12.47% | 16.55% | -0.85% | 6.16% |
| Stock price CAGR | 2% | -7% | -9% | -23% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 37.79% of Sandu Pharmaceuticals Ltd (SANDUPHQ) (unchanged from the previous quarter) and domestic institutional investors (DII) hold 0.01%. Market capitalisation was ₹40 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: SANMARK REALTY AND FINANCE PRIVATE LIMITED 5.63%, AKSHATH FINVEST AND PROPERTIES PRIVATE LIMITED 5.12%, NEELAMBER LEASING AND FINVEST PRIVATE LIMITED 4.71%, TANVI JIGNESH MEHTA 4.61%, SANBRO MARKETING SERVICES PVT LTD 2.59%, NOUMURA REALTY AND CONSTRUCTIONS PRIVATE LIMITED 2.27%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 37.79% | - | - | 0.01% | 62.21% |
| Mar 2026 | 37.79% | - | - | 0.01% | 62.21% |
| Dec 2025 | 37.79% | - | - | 0.01% | 62.21% |
| Sep 2025 | 42.9% | - | - | 0.01% | 57.1% |
| Jun 2025 | 42.9% | - | - | 0.01% | 57.1% |
| Mar 2025 | 42.9% | - | - | 0.01% | 57.1% |
| Dec 2024 | 42.9% | - | - | 0.01% | 57.1% |
| Sep 2024 | 42.9% | - | - | 0.01% | 57.1% |